Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Subscribe To Our Newsletter & Stay Updated
